The use of baseline tumor size to prognosticate overall survival in stage IV melanoma patients treated with the PD-1 inhibitor pembrolizumab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The use of baseline tumor size to prognosticate overall survival in stage IV melanoma patients treated with the PD-1 inhibitor pembrolizumab

Published:2019-03 Issue:S1 Volume:7 Page:S24-S24
ISSN:2305-5839
Container-title:Annals of Translational Medicine
language:
Short-container-title:Ann. Transl. Med

Author:

Friedlander Philip

Publisher

AME Publishing Company

Subject

General Medicine

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic impact of radiological tumor burden in patients with metastatic urothelial carcinoma treated with pembrolizumab;Urologic Oncology: Seminars and Original Investigations;2023-12

2. Prognostic significance of initial tumor shrinkage in patients with stage III non-small cell lung cancer treated with durvalumab following chemoradiotherapy;International Journal of Clinical Oncology;2023-11-30

3. Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in combination with chemotherapy;Translational Lung Cancer Research;2022-02

4. Tumour burden and efficacy of immune-checkpoint inhibitors;Nature Reviews Clinical Oncology;2021-10-12

5. Combination of Pembrolizumab with Electrochemotherapy in Cutaneous Metastases from Melanoma: A Comparative Retrospective Study from the InspECT and Slovenian Cancer Registry;Cancers;2021-08-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP